"Tubulin Modulators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.
| Descriptor ID |
D050257
|
| MeSH Number(s) |
D27.505.519.593.249.500
|
| Concept/Terms |
Tubulin Modulators- Tubulin Modulators
- Modulators, Tubulin
- Microtubule Modulators
- Modulators, Microtubule
Tubulin Promoters- Tubulin Promoters
- Promoters, Tubulin
- Tubulin Polymerization Promoters
- Polymerization Promoters, Tubulin
- Promoters, Tubulin Polymerization
Tubulin Inhibitors- Tubulin Inhibitors
- Inhibitors, Tubulin
- Tubulin Polymerization Inhibitors
- Inhibitors, Tubulin Polymerization
- Polymerization Inhibitors, Tubulin
|
Below are MeSH descriptors whose meaning is more general than "Tubulin Modulators".
Below are MeSH descriptors whose meaning is more specific than "Tubulin Modulators".
This graph shows the total number of publications written about "Tubulin Modulators" by people in this website by year, and whether "Tubulin Modulators" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tubulin Modulators" by people in Profiles.
-
ROS-mediated EB1 phosphorylation through Akt/GSK3? pathway: implication in cancer cell response to microtubule-targeting agents. Oncotarget. 2014 May 30; 5(10):3408-23.
-
Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Am Heart J. 2013 Dec; 166(6):1035-42.
-
Percutaneous coronary intervention with second-generation paclitaxel-eluting stents versus everolimus-eluting stents in United States contemporary practice (REWARDS TLX Trial). Am J Cardiol. 2012 Oct 15; 110(8):1119-24.
-
Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012 Jun 12; 125(23):2873-91.
-
Microtubule-targeted agents: when mitochondria become essential to chemotherapy. Biochim Biophys Acta. 2011 Jun; 1807(6):679-88.
-
N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamide as a new scaffold that provides rapid access to antimicrotubule agents: synthesis and evaluation of antiproliferative activity against select cancer cell lines. J Med Chem. 2010 Apr 22; 53(8):3389-95.
-
Role of cytoskeletal components in stress-relaxation behavior of adherent vascular smooth muscle cells. J Biomech Eng. 2009 Apr; 131(4):041001.
-
Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (> or =3.5 mm) coronary arteries. Am J Cardiol. 2007 Mar 01; 99(5):599-602.